Perspective Therapeutics
CATX
117 hedge funds and large institutions have $105M invested in Perspective Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 10 closing their positions.
1,543% more call options, than puts
Call options by funds: $230K | Put options by funds: $14K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
11% more funds holding
Funds holding: 105 → 117 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9.69% less ownership
Funds ownership: 58.91% → 49.21% (-9.7%)
16% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 37
30% less capital invested
Capital invested by funds: $150M → $105M (-$45M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.89M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.38M |
| 3 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$2.24M |
| 4 |
Two Sigma Investments
New York
|
+$1.94M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 2 |
Millennium Management
New York
|
-$3.29M |
| 3 |
VC
Vestor Capital
Chicago,
Illinois
|
-$2.77M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.52M |
| 5 |
JP Morgan Chase
New York
|
-$1.16M |
CATX Hedge Fund Activity: Q4 2025 in Review
117 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2025, worth a combined $105M — down 30% from $150M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CATX positions and 10 closed out — a net gain of 14 holders — while 31 added to existing stakes and 37 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.89M. The largest seller was Fidelity Investments, cutting an estimated $27.7M.
- 117 institutional investors held Perspective Therapeutics (CATX) as of Q4 2025, up from 105 in Q3 2025.
- Funds reported $105M of Perspective Therapeutics stock for Q4 2025, down 30% quarter-over-quarter.
- 24 funds opened new Perspective Therapeutics positions in Q4 2025 and 10 closed out, a net change of +14 holders.
- The largest Perspective Therapeutics buyer in Q4 2025 was Morgan Stanley, an estimated $4.89M added.
- The largest Perspective Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $27.7M sold.
Based on aggregated 13F filings for Q4 2025.